Overview

Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)

Status:
Completed
Trial end date:
2003-05-01
Target enrollment:
Participant gender:
Summary
A study to evaluate the effect of Atacand on patients with heart failure with preserved left ventricular function
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Candesartan
Candesartan cilexetil